Cullinan Therapeutics, Inc.
Total Trades
87
Buys
5
Sells
73
Largest Trade
$1M+
Insiders
11
Institutional Funds
111
Inst. Value
$1M+
Activist Filings
32
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 2K | $14.14 | Feb 26, 2026 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $50K–$100K | 5K | $14.31 | Feb 25, 2026 |
| AHMED NADIM | President and CEO | SELL | $100K–$500K | 14K | $14.47 | Feb 25, 2026 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $50K–$100K | 5K | $14.47 | Feb 25, 2026 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $50K–$100K | 4K | $14.47 | Feb 25, 2026 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $50K–$100K | 5K | $13.62 | Feb 23, 2026 |
| Michaelson Jennifer | Chief Scientific O… | EXERCISE | $15K–$50K | 8K | $4.30 | Feb 23, 2026 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $100K–$500K | 12K | $14.08 | Feb 23, 2026 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $50K–$100K | 4K | $13.62 | Feb 23, 2026 |
| AHMED NADIM | President and CEO | SELL | $100K–$500K | 16K | $13.62 | Feb 23, 2026 |
| Fenton Mary Kay | CFO | SELL | $50K–$100K | 4K | $13.62 | Feb 23, 2026 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $1K–$15K | 416 | $12.03 | Feb 13, 2026 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 4K | $12.30 | Jan 23, 2026 |
| AHMED NADIM | President and CEO | SELL | $50K–$100K | 10K | $10.01 | Dec 29, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $1K–$15K | 1K | $10.01 | Dec 22, 2025 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $15K–$50K | 3K | $9.67 | Dec 19, 2025 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $15K–$50K | 5K | $9.67 | Dec 19, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 3K | $9.67 | Dec 19, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 3K | $12.23 | Dec 16, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 4K | $12.30 | Nov 25, 2025 |
| Lynx1 Capital Management LP | 10% Owner | BUY | $1M+ | 166K | $8.40 | Oct 30, 2025 |
| Lynx1 Capital Management LP | 10% Owner | BUY | $1M+ | 249K | $8.46 | Oct 21, 2025 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $15K–$50K | 5K | $8.53 | Feb 27, 2025 |
| AHMED NADIM | President and CEO | SELL | $100K–$500K | 13K | $8.53 | Feb 27, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $15K–$50K | 4K | $8.53 | Feb 27, 2025 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $15K–$50K | 4K | $8.53 | Feb 27, 2025 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $50K–$100K | 4K | $12.51 | Jan 7, 2025 |
| AHMED NADIM | President and CEO | SELL | $50K–$100K | 8K | $11.87 | Dec 27, 2024 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $50K–$100K | 5K | $11.41 | Dec 20, 2024 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $50K–$100K | 5K | $11.41 | Dec 20, 2024 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $15K–$50K | 3K | $11.41 | Dec 20, 2024 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $100K–$500K | 8K | $15.64 | Nov 7, 2024 |
| Savill Corrine | Chief Business Off… | EXERCISE | $100K–$500K | 40K | $4.30 | Feb 3, 2024 |
| Savill Corrine | Chief Business Off… | SELL | $500K+ | 40K | $16.18 | Feb 3, 2024 |
| Savill Corrine | Chief Business Off… | EXERCISE | $100K–$500K | 40K | $4.30 | Jan 31, 2024 |
| Savill Corrine | Chief Business Off… | SELL | $500K+ | 40K | $14.09 | Jan 31, 2024 |
| Savill Corrine | Chief Business Off… | SELL | $100K–$500K | 40K | $12.31 | Jan 24, 2024 |
| Savill Corrine | Chief Business Off… | EXERCISE | $100K–$500K | 36K | $4.30 | Jan 24, 2024 |
| AHMED NADIM | President and CEO | SELL | $15K–$50K | 4K | $9.24 | Dec 27, 2023 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $15K–$50K | 2K | $8.50 | Dec 22, 2023 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $1K–$15K | 1K | $8.50 | Dec 22, 2023 |
| Trigilio Jeffrey | CFO | SELL | $15K–$50K | 2K | $8.50 | Dec 22, 2023 |
| Michaelson Jennifer | Chief Scientific O… | SELL | $1K–$15K | 1K | $8.50 | Dec 22, 2023 |
| AHMED NADIM | President and CEO | SELL | $1K–$15K | 759 | $11.40 | Jun 29, 2023 |
| Jones Jeffrey Alan | Chief Medical Offi… | SELL | $1K–$15K | 387 | $12.94 | Jun 21, 2023 |
| Michaelson Jennifer | Chief Development … | SELL | $1K–$15K | 238 | $12.94 | Jun 21, 2023 |
| Trigilio Jeffrey | CFO | SELL | $1K–$15K | 399 | $12.94 | Jun 21, 2023 |
| SUMER JACQUELYN L | Chief Legal Officer | SELL | $1K–$15K | 291 | $12.94 | Jun 21, 2023 |
| Trigilio Jeffrey | CFO | SELL | $1K–$15K | 319 | $13.11 | Jun 14, 2023 |
| Michaelson Jennifer | Chief Development … | SELL | $1K–$15K | 176 | $13.11 | Jun 14, 2023 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 111 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| MPM BioImpact LLC | 7.6M | $1M+ | SH |
| Blue Owl Capital Holdings LP | 2.4M | $1M+ | SH |
| Blue Owl Capital Holdings LP | 2.4M | $1M+ | SH |
| STATE STREET CORP | 2.2M | $1M+ | SH |
| Affinity Asset Advisors, LLC | 1.9M | $1M+ | SH |
| VR Adviser, LLC | 1.4M | $1M+ | SH |
| Siren, L.L.C. | 1.2M | $1M+ | SH |
| Nextech Invest, Ltd. | 1.1M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 797K | $1M+ | SH |
| RENAISSANCE TECHNOLOGIES LLC | 632K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 436K | $1M+ | SH |
| Point72 Asset Management, L.P. | 360K | $1M+ | SH |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 344K | $1M+ | SH |
| GOLDMAN SACHS GROUP INC | 319K | $1M+ | SH |
| ORBIMED ADVISORS LLC | 270K | $1M+ | SH |
| BARCLAYS PLC | 270K | $1M+ | SH |
| Connor, Clark & Lunn Investment Management Ltd. | 244K | $1M+ | SH |
| CITIGROUP INC | 239K | $1M+ | SH |
| PFM Health Sciences, LP | 227K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G · Mar 4, 2026
5.3%
3.1M shares
SC 13G · Jan 30, 2026
5.6%
3.3M shares
SC 13G/A · Nov 14, 2025
3.1%
1.8M shares
SC 13G/A · Nov 14, 2025
9.8%
5.8M shares
SC 13G/A · Nov 13, 2025
5.0%
2.9M shares
SC 13G/A · Oct 30, 2025
5.0%
2.9M shares
SC 13G/A · Oct 10, 2025
14.5%
8.5M shares
SC 13G · Aug 14, 2025
7.5%
4.4M shares
SC 13G · Aug 6, 2025
4.3%
2.5M shares
SC 13G/A · Nov 14, 2024
3.5%
2.0M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Nov 14, 2024
5.2%
3.0M shares
SC 13G/A · Nov 12, 2024
5.2%
3.0M shares
SC 13G · Nov 8, 2024
7.5%
4.3M shares
SC 13G/A · Nov 4, 2024
5.2%
3.0M shares
SC 13G/A · Oct 31, 2024
3.8%
2.2M shares
SC 13G · Oct 22, 2024
7.5%
4.3M shares
SC 13G/A · Jun 7, 2024
4.8%
2.7M shares
SC 13G · Apr 24, 2024
5.7%
3.3M shares
SC 13G · Feb 15, 2024
8.0%
3.4M shares
SC 13G/A · Feb 14, 2024
1.1%
469K shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2024
6.5%
2.9M shares
The Vanguard Group - 23-1945930
SC 13G/A · Feb 13, 2024
4.1%
1.8M shares
SC 13G · Jan 29, 2024
5.8%
2.5M shares
SC 13G/A · Sep 7, 2023
4.8%
2.0M shares
SC 13G/A · Feb 15, 2023
3.4%
1.6M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2023
8.9%
4.1M shares
SC 13G/A · Feb 13, 2023
7.3%
3.3M shares
SC 13G · Feb 3, 2023
5.5%
2.5M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2022
6.4%
2.8M shares
Foresite Capital Fund V, L.P. (“FCF V”)
SC 13G/A · Feb 11, 2022
2.6%
1.1M shares
SC 13G · Feb 11, 2022
5.7%
2.5M shares
SC 13G · Feb 10, 2022
4.8%
2.1M shares